In previous report, GAS6- AXL signaling has been proposed to regulate the migration of GondotropinReleasing Hormone neurons, an essential process during sexual maturation. However, the potential effect of sAXL on hormonal release in adults is not well understood. Plasma samples from five patients with MPNST and one with glioblstoma multiforme was analyzed. As a group, the levels of sAXL did not deviate from the levels of the plexiform tumors. The patient with glioblastoma had the highest sAXL level in the study, while the five MPNST patients had levels that were similar to the plexiform patients. One of the low scoring MPNST patients had the plasma drawn after surgically removing all visible sign of the tumor. The other four patients had parts of the tumors removed and were undergoing chemotherapy at the time of the plasma collection. It is unclear to what extent the ongoing therapy affected the release of AXL. Comparing the sAXL levels before and after the excision of a large plexiform neurofibroma or an MPNST would be informative on the role of sAXL as marker for these tumors. In conclusion, we report an increased expression and phosphorylation of AXL in MPNST cells with a corresponding increase in levels of sAXL in the medium when the tumor cells were grown in culture and in the mouse plasma when injected into nude mice. Further, in vivo and human studies confirmed the high correlation between the tumor burden in NF1 disease and the plasma level of sAXL. Therefore, monitoring the plasma level of sAXL may provide a useful reference for tumor growth and an accurate monitoring for treatment efficacy in NF1 patients with a plexiform neurofibroma or MPNST. Hepatocellular carcinoma is the fifth most common cancer worldwide and the third leading cause of cancer-related death. Although surgical resection is the standard treatment modality for HCC, its use is usually limited because the majority of patients, even with small HCC, have associated severe liver dysfunction. Liver transplantation provides an alternative treatment for small unresectable HCC, however, the shortage of liver grafts limits the applicability of this approach. Due to these circumstances, several non-surgical techniques have been introduced for HCC treatment, such as radiofrequency ablation, percutaneous ethanol injection and microwave coagulation therapy. Among these techniques, RFA is currently the most widely used treatment option due to its simplicity, safety, minimal invasiveness, repeatability and shorter hospital stays. RFA is considered the best option for unresectable HCC in patients with no more than three liver nodules, a NSC 136476 maximum 3 cm diameter tumor, and with preserved liver function. However, one of the major challenges with RFA is residual tumor tissue and local recurrence after local treatment, it was reported that the post-RFA recurrent rates range from 49 to 74%. Moreover, the local recurrent tumor after RFA showed a more invasive growth, more vascular invasion and less differentiation compared with tumors of patients without RFA. The Wnt/b-catenin pathway is an important signaling pathway in HCC.